Phase 2 Rare Disease Trial, Not Yet Recruiting NCT07750990 Sponsor: Shionogi Condition: Rare Disease
Back to Rare Disease

Phase 2 Rare Disease Trial, Not Yet Recruiting

NCT07750990
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who weigh at least 40 kilograms at the time of signing the consent forms to participate.
  • People who have previously completed a clinical study involving a treatment called S-606001 for Pompe disease, including those whose assigned treatment group was stopped by the company running the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a medical condition or other circumstance that, in the opinion of the trial doctor or medical monitor, could pose a safety risk or make it difficult to follow the trial's requirements.
  • People who are currently enrolled in another clinical study that involves an investigational treatment or any other type of medical research.
  • Women who are pregnant or breastfeeding at the time of the first visit.
  • People of any gender who are planning to have a child during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 August 2026

Contact this trial

Principal Investigator: Medical Director, Shionogi Inc.

Phone: 1-800-849-9707

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Shionogi
Registry
ClinicalTrials.gov
Start date
31 August 2026
Est. completion
31 August 2028

Primary endpoints

Number of Participants With Treatment-emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov